Peptide Therapy: BPC-157, CJC-1295, and Ipamorelin -- What the Evidence Actually Says

Peptide therapy is one of the louder corners of functional and longevity medicine right now. Walk through a wellness clinic in any major city and you will hear the same names repeated: BPC-157 for healing, CJC-1295 with ipamorelin for growth hormone, ozempic-this, peptide-that. Some of it is grounded in interesting biology. Some of it is well ahead of the human evidence.

This is a fair-witness summary of where the science actually sits in 2026, what these peptides can plausibly do, what the risks are, and how a clinician should think about them. We will not be selling you anything. The goal is to help you tell honest evidence from marketing copy.

What peptides actually are

A peptide is a short chain of amino acids, typically fewer than 50, that signals other cells. Insulin is a peptide. So is glucagon, oxytocin, GLP-1, and dozens of other endogenous messengers. The term "peptide therapy" usually refers to synthetic peptides administered, almost always by subcutaneous injection, to push a specific receptor or pathway.

That sounds elegant. The catch is that the peptide world ranges from FDA-approved drugs (semaglutide, tirzepatide, tesamorelin) to research compounds with very limited human data being sold by compounding pharmacies and, less responsibly, by online research-chemical sites. The label "peptide" tells you almost nothing about how well-studied or safe a given molecule is.

Three peptides dominate the conversation in functional medicine right now: BPC-157, CJC-1295, and ipamorelin. They get bundled in marketing as if they were a class. Mechanistically they are not. We will take them one at a time.

BPC-157

BPC-157 stands for "body protection compound." It is a 15-amino-acid fragment derived from a protein found in human gastric juice. Preclinical work, almost entirely in rats and mice, suggests it accelerates healing of muscle, tendon, ligament, gut lining, and even some neural tissue, partly through angiogenesis (new blood vessel formation) and partly through nitric oxide and growth factor pathways [9]. The mechanistic story is interesting and consistent across labs.

Now the honest part. A 2025 systematic review pulled 36 BPC-157 studies through June 2024. Thirty-five were preclinical. One was a single human study [1]. Let that land. After thirty-plus years of research, the human evidence base for BPC-157 is essentially one published clinical study, plus a 2025 pilot in two healthy adults receiving IV BPC-157 up to 20 mg, which reported no acute adverse events but established nothing about efficacy. That is not a data set you can build clinical decisions on. It is a starting line.

The biology in animals is encouraging enough that several investigators are trying to move into proper trials. Until those read out, anything you read about BPC-157 reversing tendinopathy, healing chronic gut issues, or rescuing brain injury is, at best, a reasonable hypothesis based on rodent work [1, 2, 9]. It is not a clinical fact.

A second issue: regulatory status. The FDA placed BPC-157 on its Category 2 list of bulk drug substances flagged for significant safety concerns, which means licensed 503A compounding pharmacies are not permitted to compound it for human use [8]. In February 2026, HHS announced an intent to reclassify it back toward Category 1, but as of this writing no formal rule has been published. WADA also prohibits BPC-157 in competition athletes under category S0 (non-approved substances) [10].

Where does that leave a careful clinician? With caution. We do not believe the existing rodent data justifies casual use in humans for vague indications, and we are not in the business of importing research-grade material. If BPC-157 ever gets a real Phase 2 readout in humans for a defined indication (Achilles tendinopathy is the most likely first target), the conversation will change.

CJC-1295 and ipamorelin

These two get prescribed together for one reason: they push growth hormone (GH) release through different mechanisms, and the combination produces a larger, more physiologic GH pulse than either alone.

CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors in the pituitary and tells the gland to release stored GH. The "DAC" version (drug affinity complex) sticks to albumin and lasts days. The non-DAC version (modified GRF 1-29) lasts hours, which is why most clinicians use the shorter form to preserve a more natural pulse pattern.

The strongest human pharmacokinetic data on CJC-1295 comes from two trials. A 2006 Phase 1 in healthy adults showed dose-dependent 2- to 10-fold increases in plasma GH and 1.5- to 3-fold increases in IGF-1, sustained for 6 to 11 days after a single dose, with reasonable tolerability at 30 to 60 mcg/kg [3]. A follow-up showed pulsatile GH release was preserved during continuous CJC-1295 stimulation [4]. The drug development program advanced into Phase 2 for HIV lipodystrophy and growth hormone deficiency. It was discontinued after one trial subject died, with the attending physician attributing the event to coronary artery disease unrelated to study drug, though the program never resumed.

Ipamorelin is a pentapeptide ghrelin-receptor agonist. It tells the pituitary to release GH through the GH-secretagogue pathway, which is independent of GHRH. The 1998 paper that introduced it to the literature showed it released GH selectively without significantly raising cortisol or prolactin, which is the practical advantage over older secretagogues [5]. Combine GHRH-pathway stimulation (CJC-1295) with ghrelin-pathway stimulation (ipamorelin) and you get a more pronounced GH pulse than either alone.

Now the careful part. Most human evidence for therapeutic GH-axis stimulation in adults comes from a different molecule: tesamorelin, an FDA-approved GHRH analog studied in HIV-associated visceral fat. The Phase 3 program enrolled hundreds of patients and showed roughly 15 percent visceral fat reduction over 26 weeks versus placebo, alongside triglyceride improvements [6]. Tesamorelin tells us the GHRH-stimulation strategy can work in a defined population. It does not, by itself, validate CJC-1295 plus ipamorelin for body composition or "anti-aging" use in healthy adults. The trials addressing those exact indications are small or non-existent.

What you can reasonably say from the data:

• CJC-1295 raises plasma GH and IGF-1 in humans for several days per dose [3, 4]
• Ipamorelin selectively stimulates GH release without significant cortisol or prolactin elevation [5]
• The combination produces synergistic GH pulses in animal and limited human work
• We do not have large randomized human trials showing clinically meaningful benefit on lean mass, fat mass, sleep quality, or recovery in otherwise healthy adults

What you cannot reasonably say:

• That these peptides reverse aging
• That they replace exogenous GH for diagnosed adult GH deficiency, which still requires daily recombinant GH per Endocrine Society guidance [7]
• That they are risk-free over multi-year use, because nobody has the long-term data

The Endocrine Society guideline for adult GH deficiency is worth reading because it sets a useful frame. Diagnosed adult GHD is a real clinical entity with structural causes (pituitary adenoma, prior cranial irradiation, traumatic brain injury), specific testing (insulin tolerance test or alternative stimulation tests), and an established treatment (daily recombinant human GH injections) [7]. Most patients asking us about CJC-1295 plus ipamorelin do not have diagnosed GHD. They have age-related GH decline, which is normal physiology, not disease.

That distinction matters. The question is not whether you can push a 50-year-old's GH and IGF-1 levels closer to those of a 25-year-old. You can. The question is whether doing so produces durable clinical benefit without long-term harm, and that question does not have an answer yet.

Forms, dosing, and how clinicians actually run protocols

For CJC-1295 (no DAC) plus ipamorelin, the most common clinical pattern looks like this:

• Subcutaneous injection 5 nights per week, before bed
• Roughly 100 to 200 mcg of CJC-1295 plus 100 to 300 mcg of ipamorelin per dose
• 8 to 12 week cycles, often with a break
• Baseline labs including IGF-1, fasting glucose, A1c, lipids, and a basic metabolic panel; recheck IGF-1 at 8 to 12 weeks

For BPC-157, where we use it at all, the most-studied animal route is intramuscular or subcutaneous near the injury site, at doses extrapolated from rodent studies. The honest framing for patients is that human dosing is essentially unvalidated. We are extrapolating.

Tesamorelin, by contrast, has FDA-approved dosing (2 mg subcutaneously daily) and is a different conversation. We mention it because if a patient genuinely needs GHRH-axis support and qualifies under the approved indication, that is a regulated drug with real human data, not a compounded peptide.

Realistic expectations

What patients on a CJC-1295 plus ipamorelin protocol commonly report over 8 to 12 weeks:

• Better sleep depth, especially in the first half of the night
• Modest improvements in body composition when paired with adequate protein and resistance training
• Subjective improvements in recovery between training sessions

What patients should not expect:

• Dramatic muscle gain
• Weight loss without dietary change
• Reversal of age-related changes in skin, joints, or cognition
• Anything close to the effects of supraphysiologic exogenous GH

The placebo response in this space is real. Patients want to feel better, they are paying for an injection they administer themselves, and they are often improving sleep and training simultaneously. Untangling drug effect from lifestyle effect is hard, which is why we recommend repeat IGF-1 levels and objective markers (sleep tracking, training logs, body composition) rather than relying on subjective impressions alone.

Risks and safety

Short-term safety in published trials has been reasonable. CJC-1295 caused mild injection-site reactions, occasional flushing, and mild headache in early trials at doses up to 60 mcg/kg [3]. Ipamorelin's safety profile in published work is similar [5]. The 2025 IV BPC-157 pilot in two adults reported no acute adverse events, though n=2 is not a safety signal in either direction [1].

Theoretical and practical concerns worth naming:

• IGF-1 and proliferation. GH and IGF-1 promote cellular growth. The concern that elevated IGF-1 over years could promote occult cancers is biologically plausible and unresolved. We monitor IGF-1 and avoid these peptides in anyone with active or recent cancer.
• Insulin resistance. Sustained GH elevation can blunt insulin sensitivity. We watch fasting glucose and A1c, and we are cautious in patients with prediabetes or metabolic syndrome.
• Retinopathy. GH can worsen proliferative retinopathy. We avoid in active diabetic eye disease.
• Source quality. Compounded peptides from licensed 503A pharmacies follow USP standards. Research-grade material from online vendors does not. Counterfeiting and contamination are real, well-documented problems in the gray-market peptide space.
• Banned in competition. WADA prohibits both growth hormone secretagogues and BPC-157 in athletes subject to anti-doping testing [10].

A long-term safety concern that bears repeating: nobody has run a 10-year prospective study of CJC-1295 plus ipamorelin in healthy adults. Drawing strong safety conclusions from short trials in small populations is not the same as having long-term outcome data.

Who is and isn't a candidate

Reasonable candidates for a structured trial of CJC-1295 plus ipamorelin under medical supervision:

• Healthy adults over 35 with persistent recovery issues despite good training and nutrition
• Patients with low-normal IGF-1, no contraindications, and a willingness to track objective markers
• Patients in a longevity program where the peptides are one tool among many, not the entire plan

Not appropriate:

• Active or recent cancer
• Pregnancy or breastfeeding
• Active retinopathy or untreated diabetic eye disease
• Significant insulin resistance, prediabetes, or uncontrolled diabetes
• Patients seeking dramatic body recomposition who are unwilling to address training, sleep, and nutrition first
• Anyone subject to WADA testing in competition

For BPC-157, given current evidence and regulatory status, our default position is conservative. We do not consider it standard of care. We discuss it honestly when patients ask, including the FDA Category 2 status and the absence of human efficacy data [1, 8].

Cost

Real-world ranges in the United States, assuming a reputable compounding source and clinician oversight:

• CJC-1295 plus ipamorelin combo: roughly $300 to $500 per month, depending on dose and pharmacy
• Initial consult plus baseline labs: $300 to $600 one-time
• Follow-up labs every 8 to 12 weeks: $150 to $300

If a clinic offers peptide therapy at a fraction of that, ask hard questions about sourcing. If a website offers research-grade peptides direct to consumers, that is not a medical service, that is a regulatory and safety problem.

How we approach peptides at NoMi Beach Health

Our position is cautiously optimistic and deliberately narrow. We discuss CJC-1295 plus ipamorelin with patients who have realistic expectations and no contraindications. We use compounding pharmacies that follow USP standards. We baseline IGF-1, fasting glucose, A1c, lipids, and a CMP, and we recheck IGF-1 at 8 to 12 weeks. We pair the protocol with sleep, training, and nutrition coaching, because peptides without those basics rarely do much.

We are conservative on BPC-157. Until human evidence catches up, we lean toward standard-of-care musculoskeletal treatment (rehab, targeted injections where indicated, time) rather than experimental peptides for soft tissue healing.

For patients who genuinely have diagnosed adult growth hormone deficiency, the right conversation is not peptides. It is endocrinology referral and, if confirmed, treatment with FDA-approved recombinant human GH per the Endocrine Society guideline [7]. That is a different medicine.

Closing thought

Peptide therapy is real biology with limited human evidence. The right posture is curiosity plus skepticism. CJC-1295 plus ipamorelin can plausibly support sleep and recovery in selected adults, with monitoring. BPC-157 is mostly rodent data and regulatory uncertainty. None of it replaces sleep, training, protein, hormonal optimization where indicated, and the unglamorous fundamentals.

If you are curious whether peptides fit your goals, book a consult and we will walk through your labs, your history, and what would actually be useful. We would rather you do less and do it right.